Through a cooperation with the German biotech company Curevac, Tesla is also involved in the development of vaccines against the coronavirus – not directly in the medical development and testing of substances, but in their subsequent production in small RNA factories. The German partner is now using the second generation of a bioreactor, which is required for the production of an mRNA vaccine, informed Tesla CEO Elon Musk this week that the third generation is currently in development.
Important, not big business for Tesla
He expects this technology to be of great importance for the world, Musk wrote on Twitter – but not in financial terms for Tesla. The CEO of Tesla and SpaceX expressed again that he does not strive for personal wealth with these billionaire companies, but wants to do good. He describes the purpose of his life in making the world a better place.
The German university spin-off Curevac is majority owned by SAP co-founder Dietmar Hopp and is currently developing an RNA vaccine against the coronavirus, among other things. Another German biotech company, Biontech, is also working on such a vaccine and only reported promising results of an efficacy study this week.
Hopp first became known to the public as an enemy of fans of the TSG Hoffenheim football club. With the first success reports on vaccine research at Curevac, his work in this area came to the fore. This September, the first report was made about a cooperation between the Tübingen-based company and Tesla via the German subsidiary Grohmann. During his visit to Germany this summer, Musk was also at the Curevac headquarters.